VM:CC - Voyageur Pharmaceuticals Ltd. Announces Filing of Interim Financial Statements Director Changes and Grant of Stock Options

(TheNewswire)

Calgary, Alberta - TheNewswire - August 1, 2023 - Voyageur Pharmaceuticals Ltd. ( TSX.V:VM )( USA: VYYRF ) (the " Company " or" Voyageur ") announces that it has filed its interim financialstatements and management's discussion and analysis for the quarterended May 31, 2023 on SEDAR+ (www.sedarplus.ca).

Voyageur also announces the retirement from the Boardof Directors of the Corporation (the " Board ") of RonSifton who has served the Company well for the last three and a halfyears as a member of the Board and as Chairman of the Audit Committee,and member of the Compensation Committee and Corporate GovernanceCommittee. Mr. Sifton received special thanks from the Board membersand management and best wishes in his retirement.

The Company is pleased to announce that Kevin R.McBeth, CPA, CA, ICD.D, subject to regulatory approval, has joined theBoard and will take on the role of Chair of the Audit Committee aswell as member of the Compensation Committee. Kevin is an accomplished and esteemed professional with adiverse background in finance, accounting, and corporate governance.With an extensive track record in the industry, Kevin has earned areputation as a trusted advisor and distinguished leader.

As a Certified Public Accountant (CPA) and CharteredAccountant (CA), Kevin possesses an in-depth understanding offinancial management, reporting, and compliance. His proficiency liesin effectively managing complex financial operations, ensuring utmostaccuracy and transparency in financial statements, and implementingrobust internal controls.

Kevin's unwavering commitment to excellence and hisdedication to professional growth drove him to achieve the prestigiousICD.D (Institute of Corporate Directors) designation. This credentialshowcases his comprehensive knowledge of corporate governancepractices, enabling him to provide strategic guidance to boards ofdirectors. With this certification, Kevin is excellently equipped tocontribute to the effective governance and long-term prosperity ofVoyageur.

Throughout his career, Kevin has held various executivepositions, showcasing his leadership skills and business acumen.Serving as Chief Financial Officer (CFO) for prominent companies, heexpertly oversees financial planning and analysis, budgeting, riskmanagement, and successful mergers and acquisitions. His sharpfinancial insights, combined with a strategic mindset, have drivenremarkable growth, and optimized financial performance for theorganizations he has collaborated with.

Beyond his professional achievements, Kevin activelyengages in community initiatives and philanthropic endeavors. Drivenby a strong belief in giving back to society, he endeavors to make apositive impact through his thoughtful contributions.

Option Grant

Voyageur announced that it has issued 300,000 stockoptions (the " Options ") to directors of the Companypursuant to its incentive stock option plan. On July 20, 2023, theBoard approved the grant of Options, to be effective on July 28, 2023using the closing price on that day. The Options were issued with anexercise price of $0.065 per common share, vest immediately, and havea 10-year term.  The Options are subject to regulatory and TSXVenture Exchange approval.

About Voyageur

Voyageur is a Canadian public company listed on theTSXV under the trading symbol VM. Voyageur is focused on thedevelopment of barium and iodine Active Pharmaceutical Ingredients(“API”) and high-performance cost-effective imaging contrastagents for the medical imaging marketplace. Voyageur’s goal is tofully integrate the barium and iodine contrastmarket by producing its own minerals of barium and iodine. Thebusiness plan is to initially generate cash flow from operations usingthird party GMP pharmaceutical manufacturers in Canada and validatethe products for regulatory agencies globally. Then transitioning intoa high margin domestic manufacturer of radiology drugs. Voyageur hasplans to build carbon neutral infrastructure to become 100%self-sufficient across all manufacturing activities. Voyageur owns a100% interest in three barium sulphate (barite) projects including theFrances Creek property, suitable in grade for the pharmaceuticalmarketplace, with additional interests in a high-grade iodine, lithium& bromine brine project located in Utah, USA. Voyageur is movingforward with its business plan of becoming the only fully integratedcarbon neutral company in the radiology contrast media drug market, bycontrolling all primary input costs under the motto of: "From the Earth to theBottle".

Cautionary Statement Regarding“Forward-Looking” Information

This news releasemay contain certain forward-looking information and statementsincluding statements regarding regulatory approval of the appointmentof Kevin McBeth as a director and the stock option grants. Allstatements included herein, other than statements of historical fact,are forward-looking information and such information involves variousrisks and uncertainties. There can be no assurance that suchinformation will prove to be accurate, and actual results and futureevents could differ materially from those anticipated in suchinformation. A description of assumptions used to develop suchforward-looking information and a description of risk factors that maycause actual results to differ materially from forward-lookinginformation can be found in the Company's disclosure documents on theSEDAR+ website at www.sedarplus.ca. Voyageur does not undertake toupdate any forward-looking information except in accordance withapplicable securities laws.

Copyright (c) 2023 TheNewswire - All rights reserved.